Search research articles
Contact Us
Filters
Showing results (1-10 of 15) with videos related to
Page
of 2
Sort By:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
June 16, 2022
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?
Nahum Mendez-Sanchez, Shreya C Pal
World Journal of Gastroenterology
|
July 21, 2023
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
Shreya C Pal, Nahum Méndez-Sánchez
Therapeutic Advances in Endocrinology and Metabolism
|
January 26, 2023
Screening for MAFLD: who, when and how?
Shreya C Pal, Nahum Méndez-Sánchez
Journal of Hepatology
|
August 21, 2022
New terms for fatty liver disease other than MAFLD: Time for a reality check
Nahum Méndez-Sánchez, Shreya C Pal
Hormones (Athens, Greece)
|
August 28, 2022
Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Hormones (Athens, Greece)
|
August 3, 2022
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Annals of Hepatology
|
December 2, 2022
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria
Nahum Méndez-Sánchez, Eduardo Fassio, Shreya C Pal
Expert Opinion on Pharmacotherapy
|
April 24, 2023
How far are we from an approved drug for nonalcoholic steatohepatitis?
Nahum Méndez-Sánchez, Shreya C Pal, Jacqueline Córdova-Gallardo
Expert Review of Gastroenterology & Hepatology
|
August 13, 2025
Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD)
Shreya C Pal, Mariana M Ramírez-Mejía, Andrew P Keaveny, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
September 12, 2022
Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Ana Luisa Ordóñez-Vázquez, Sofía Murúa Beltrán-Gall, Shreya C Pal, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 15) with videos related to
Sort By:
Page
of 2
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
June 16, 2022
Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?
Nahum Mendez-Sanchez, Shreya C Pal
World Journal of Gastroenterology
|
July 21, 2023
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
Shreya C Pal, Nahum Méndez-Sánchez
Therapeutic Advances in Endocrinology and Metabolism
|
January 26, 2023
Screening for MAFLD: who, when and how?
Shreya C Pal, Nahum Méndez-Sánchez
Journal of Hepatology
|
August 21, 2022
New terms for fatty liver disease other than MAFLD: Time for a reality check
Nahum Méndez-Sánchez, Shreya C Pal
Hormones (Athens, Greece)
|
August 28, 2022
Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Hormones (Athens, Greece)
|
August 3, 2022
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Shreya C Pal, Mohammed Eslam, Nahum Mendez-Sanchez
Annals of Hepatology
|
December 2, 2022
Interpretive bias on research evidence: Striving to meet the trustworthiness criteria
Nahum Méndez-Sánchez, Eduardo Fassio, Shreya C Pal
Expert Opinion on Pharmacotherapy
|
April 24, 2023
How far are we from an approved drug for nonalcoholic steatohepatitis?
Nahum Méndez-Sánchez, Shreya C Pal, Jacqueline Córdova-Gallardo
Expert Review of Gastroenterology & Hepatology
|
August 13, 2025
Non-invasive biomarkers for monitoring portal hypertension in metabolic dysfunction-associated steatotic liver disease (MASLD)
Shreya C Pal, Mariana M Ramírez-Mejía, Andrew P Keaveny, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|
September 12, 2022
Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Ana Luisa Ordóñez-Vázquez, Sofía Murúa Beltrán-Gall, Shreya C Pal, et al.
Page
of 2